Oxorhenium(V) complexes in the drug combination study
Autori
Petrović, TamaraGligorijević, Nevenka
Belaj, Ferdinand
Grgurić-Šipka, Sanja
Nikolić, Stefan
Krstić, Milena
Poljarević, Jelena
Mihajlović-Lalić, Ljiljana
Konferencijski prilog (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Rhenium complexes merit particular attention in the area of metallodrug design due to rhenium’s broad spectrum of oxidation states and consequently, the possibility to design compounds of a great structural diversity. Thus, the synthesis, chemical characterization and antitumor activity in vitro of the three Re(V) complexes is described. Novel compounds were obtained via reaction of [ReOCl3(PPh3)2] with corresponding ligands (pyridine-2-carboxylic acid, 3-methylpyridine-2-carboxylic acid and 6-methylpyridine-2-carboxylic acid) in acetonitrile at 78 °C for 3h. The complexes were fully characterized using NMR, IR, MS and elemental analysis. Their octahedral geometry with bidentate NO ligand was confirmed by X-ray diffraction analysis. Antiproliferative effect was determined by MTT assay and only the complex with pyridine-2-carboxylic acid (1) showed dose-dependent cytotoxic potential, particularly toward triple-negative breast adenocarcinoma cells MDA-MB-231 with IC50 68.90 ± 1.73 µM and... pancreatic adenocarcinoma cells PANC-1 with IC50 69.8 ± 2.3 µM. Drug combination studies in PANC-1 cells with 1 and Verapamil hydrochloride (VRP) showed slight arrest of cell cycle in the S phase and also it increase its antiproliferative potential to IC50 51.4 ± 2.8 μM. Part of the research included a depletion of the glutathione (GSH) level by L-buthionine-sulfoximine (L-BSO) at sub-toxic concentrations (100 μM) in PANC-1 cells which caused an increase of activity of 1 to the IC50 57.67 ± 6.51 μM.
Izvor:
8 th Conference of Young Chemists of Serbia Belgrade, 29th October 2022, 2022, 81-81Izdavač:
- Belgrade : Serbian Chemical Society
- Belgrade : Serbian Young Chemists’ Club
Finansiranje / projekti:
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200288 (Inovacioni centar Hemijskog fakulteta u Beogradu doo) (RS-MESTD-inst-2020-200288)
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200168 (Univerzitet u Beogradu, Hemijski fakultet) (RS-MESTD-inst-2020-200168)
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200043 (Institut za onkologiju i radiologiju Srbije, Beograd) (RS-MESTD-inst-2020-200043)
Kolekcije
Institucija/grupa
Hemijski fakultet / Faculty of ChemistryTY - CONF AU - Petrović, Tamara AU - Gligorijević, Nevenka AU - Belaj, Ferdinand AU - Grgurić-Šipka, Sanja AU - Nikolić, Stefan AU - Krstić, Milena AU - Poljarević, Jelena AU - Mihajlović-Lalić, Ljiljana PY - 2022 UR - http://cherry.chem.bg.ac.rs/handle/123456789/5824 AB - Rhenium complexes merit particular attention in the area of metallodrug design due to rhenium’s broad spectrum of oxidation states and consequently, the possibility to design compounds of a great structural diversity. Thus, the synthesis, chemical characterization and antitumor activity in vitro of the three Re(V) complexes is described. Novel compounds were obtained via reaction of [ReOCl3(PPh3)2] with corresponding ligands (pyridine-2-carboxylic acid, 3-methylpyridine-2-carboxylic acid and 6-methylpyridine-2-carboxylic acid) in acetonitrile at 78 °C for 3h. The complexes were fully characterized using NMR, IR, MS and elemental analysis. Their octahedral geometry with bidentate NO ligand was confirmed by X-ray diffraction analysis. Antiproliferative effect was determined by MTT assay and only the complex with pyridine-2-carboxylic acid (1) showed dose-dependent cytotoxic potential, particularly toward triple-negative breast adenocarcinoma cells MDA-MB-231 with IC50 68.90 ± 1.73 µM and pancreatic adenocarcinoma cells PANC-1 with IC50 69.8 ± 2.3 µM. Drug combination studies in PANC-1 cells with 1 and Verapamil hydrochloride (VRP) showed slight arrest of cell cycle in the S phase and also it increase its antiproliferative potential to IC50 51.4 ± 2.8 μM. Part of the research included a depletion of the glutathione (GSH) level by L-buthionine-sulfoximine (L-BSO) at sub-toxic concentrations (100 μM) in PANC-1 cells which caused an increase of activity of 1 to the IC50 57.67 ± 6.51 μM. PB - Belgrade : Serbian Chemical Society PB - Belgrade : Serbian Young Chemists’ Club C3 - 8 th Conference of Young Chemists of Serbia Belgrade, 29th October 2022 T1 - Oxorhenium(V) complexes in the drug combination study SP - 81 EP - 81 UR - https://hdl.handle.net/21.15107/rcub_cherry_5824 ER -
@conference{ author = "Petrović, Tamara and Gligorijević, Nevenka and Belaj, Ferdinand and Grgurić-Šipka, Sanja and Nikolić, Stefan and Krstić, Milena and Poljarević, Jelena and Mihajlović-Lalić, Ljiljana", year = "2022", abstract = "Rhenium complexes merit particular attention in the area of metallodrug design due to rhenium’s broad spectrum of oxidation states and consequently, the possibility to design compounds of a great structural diversity. Thus, the synthesis, chemical characterization and antitumor activity in vitro of the three Re(V) complexes is described. Novel compounds were obtained via reaction of [ReOCl3(PPh3)2] with corresponding ligands (pyridine-2-carboxylic acid, 3-methylpyridine-2-carboxylic acid and 6-methylpyridine-2-carboxylic acid) in acetonitrile at 78 °C for 3h. The complexes were fully characterized using NMR, IR, MS and elemental analysis. Their octahedral geometry with bidentate NO ligand was confirmed by X-ray diffraction analysis. Antiproliferative effect was determined by MTT assay and only the complex with pyridine-2-carboxylic acid (1) showed dose-dependent cytotoxic potential, particularly toward triple-negative breast adenocarcinoma cells MDA-MB-231 with IC50 68.90 ± 1.73 µM and pancreatic adenocarcinoma cells PANC-1 with IC50 69.8 ± 2.3 µM. Drug combination studies in PANC-1 cells with 1 and Verapamil hydrochloride (VRP) showed slight arrest of cell cycle in the S phase and also it increase its antiproliferative potential to IC50 51.4 ± 2.8 μM. Part of the research included a depletion of the glutathione (GSH) level by L-buthionine-sulfoximine (L-BSO) at sub-toxic concentrations (100 μM) in PANC-1 cells which caused an increase of activity of 1 to the IC50 57.67 ± 6.51 μM.", publisher = "Belgrade : Serbian Chemical Society, Belgrade : Serbian Young Chemists’ Club", journal = "8 th Conference of Young Chemists of Serbia Belgrade, 29th October 2022", title = "Oxorhenium(V) complexes in the drug combination study", pages = "81-81", url = "https://hdl.handle.net/21.15107/rcub_cherry_5824" }
Petrović, T., Gligorijević, N., Belaj, F., Grgurić-Šipka, S., Nikolić, S., Krstić, M., Poljarević, J.,& Mihajlović-Lalić, L.. (2022). Oxorhenium(V) complexes in the drug combination study. in 8 th Conference of Young Chemists of Serbia Belgrade, 29th October 2022 Belgrade : Serbian Chemical Society., 81-81. https://hdl.handle.net/21.15107/rcub_cherry_5824
Petrović T, Gligorijević N, Belaj F, Grgurić-Šipka S, Nikolić S, Krstić M, Poljarević J, Mihajlović-Lalić L. Oxorhenium(V) complexes in the drug combination study. in 8 th Conference of Young Chemists of Serbia Belgrade, 29th October 2022. 2022;:81-81. https://hdl.handle.net/21.15107/rcub_cherry_5824 .
Petrović, Tamara, Gligorijević, Nevenka, Belaj, Ferdinand, Grgurić-Šipka, Sanja, Nikolić, Stefan, Krstić, Milena, Poljarević, Jelena, Mihajlović-Lalić, Ljiljana, "Oxorhenium(V) complexes in the drug combination study" in 8 th Conference of Young Chemists of Serbia Belgrade, 29th October 2022 (2022):81-81, https://hdl.handle.net/21.15107/rcub_cherry_5824 .